image
Technology - Software - Infrastructure - NASDAQ - IL
$ 17.7
-1.45 %
$ 3.68 B
Market Cap
-11.35
P/E
1. INTRINSIC VALUE

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions.[ Read More ]

The intrinsic value of one CLBT stock under the base case scenario is HIDDEN Compared to the current market price of 17.7 USD, Cellebrite DI Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLBT

image
FINANCIALS
325 M REVENUE
20.12%
33.2 M OPERATING INCOME
3083.62%
-81.1 M NET INCOME
-67.13%
102 M OPERATING CASH FLOW
395.98%
-22.5 M INVESTING CASH FLOW
75.29%
21.8 M FINANCING CASH FLOW
55.80%
107 M REVENUE
11.64%
19.4 M OPERATING INCOME
55.72%
-207 M NET INCOME
-769.74%
41.6 M OPERATING CASH FLOW
186.98%
-18.7 M INVESTING CASH FLOW
43.89%
5.53 M FINANCING CASH FLOW
66.31%
Balance Sheet Decomposition Cellebrite DI Ltd.
image
Current Assets 417 M
Cash & Short-Term Investments 303 M
Receivables 77.3 M
Other Current Assets 36.3 M
Non-Current Assets 124 M
Long-Term Investments 28.9 M
PP&E 30.2 M
Other Non-Current Assets 64.8 M
Current Liabilities 254 M
Accounts Payable 8.28 M
Short-Term Debt 4.97 M
Other Current Liabilities 241 M
Non-Current Liabilities 252 M
Long-Term Debt 9.16 M
Other Non-Current Liabilities 243 M
EFFICIENCY
Earnings Waterfall Cellebrite DI Ltd.
image
Revenue 325 M
Cost Of Revenue 53.2 M
Gross Profit 272 M
Operating Expenses 239 M
Operating Income 33.2 M
Other Expenses 114 M
Net Income -81.1 M
RATIOS
83.63% GROSS MARGIN
83.63%
10.22% OPERATING MARGIN
10.22%
-24.95% NET MARGIN
-24.95%
-237.05% ROE
-237.05%
-15.01% ROA
-15.01%
104.27% ROIC
104.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cellebrite DI Ltd.
image
Net Income -81.1 M
Depreciation & Amortization 10 M
Capital Expenditures -7.92 M
Stock-Based Compensation 19 M
Change in Working Capital 38.5 M
Others 142 M
Free Cash Flow 94.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cellebrite DI Ltd.
image
Wall Street analysts predict an average 1-year price target for CLBT of $18.6 , with forecasts ranging from a low of $16 to a high of $23 .
CLBT Lowest Price Target Wall Street Target
16 USD -9.60%
CLBT Average Price Target Wall Street Target
18.6 USD 5.08%
CLBT Highest Price Target Wall Street Target
23 USD 29.94%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Cellebrite DI Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
NU or CLBT: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Technology Services sector might want to consider either Nu Holdings Ltd. (NU) or Cellebrite DI Ltd. zacks.com - 5 days ago
Cellebrite DI: Long-Term Growth Looks Positive, But Valuation Increased I previously rated Cellebrite DI a 'strong buy' due to its growth potential and attractive valuation. Since my recommendation, Cellebrite has outperformed, with the stock rising 160% compared to the S&P 500's 33% increase. Cellebrite has positive developments from its Q3 2024 earnings report. seekingalpha.com - 5 days ago
Cellebrite: There Are Potential Risks That Could Damper Growth I maintain a neutral rating on Cellebrite due to its premium valuation and risks from CEO transition and potential federal budget cuts. Despite solid growth, including a 27% revenue increase and expanding margins, uncertainties around leadership and federal funding impact my outlook. Strong adoption of Inseyets, Guardian, and Pathfinder products, with notable ARR growth, suggests a long growth runway ahead. seekingalpha.com - 1 week ago
Cellebrite DI Ltd. (CLBT) Q3 2024 Earnings Call Transcript Cellebrite DI Ltd. (NASDAQ:CLBT ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Andrew Kramer - Investor Relations Yossi Carmil - CEO Dana Gerner - CFO Thomas Hogan - Executive Chairman Conference Call Participants Shaul Eyal - TD Cowen Michael Cikos - Needham Jeffrey Van Rhee - Craig-Hallum Brian Essex - JP Morgan Jonathan Ho - William Blair Tomer Zilberman - Bank of America Max Michaels - Lake Street Capital Operator Welcome to the Cellebrite Third Quarter 2024 Financial Results Conference Call. seekingalpha.com - 1 week ago
Cellebrite DI Ltd. (CLBT) Tops Q3 Earnings and Revenue Estimates Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. zacks.com - 1 week ago
CORRECTION: Cellebrite Announces Third-Quarter 2024 Results Third- q uarter 2024 r evenue of $106.9 million exceeds $100 million quarterly revenue milestone  for the first time in Company history globenewswire.com - 1 week ago
Yossi Carmil to Step Down as CEO After Nearly 20 Years TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced a planned leadership transition following Yossi Carmil's decision to step down from his current role as CEO and as a member of the Board of Directors by December 31, 2024. globenewswire.com - 1 week ago
What Makes Cellebrite DI Ltd. (CLBT) a New Strong Buy Stock Cellebrite DI Ltd. (CLBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 1 month ago
Cellebrite to Report Third-Quarter 2024 Financial Results on November 6, 2024 TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its third-quarter 2024 financial results before market open on Wednesday, November 6, 2024. globenewswire.com - 1 month ago
Cellebrite DI Ltd. (CLBT) Hit a 52 Week High, Can the Run Continue? Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future? zacks.com - 1 month ago
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year? Here is how Cellebrite DI Ltd. (CLBT) and Nexxen International Ltd. zacks.com - 1 month ago
Cellebrite Patents its Remote Mobile Collection Capabilities for Businesses Remote Mobile Collection enables faster device access and analysis, saving corporate investigators time and money Remote Mobile Collection enables faster device access and analysis, saving corporate investigators time and money globenewswire.com - 1 month ago
8. Profile Summary

Cellebrite DI Ltd. CLBT

image
COUNTRY IL
INDUSTRY Software - Infrastructure
MARKET CAP $ 3.68 B
Dividend Yield 0.00%
Description Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.
Contact 94 Shlomo Shmelzer Road, Petah Tikva, 4970602 https://www.cellebrite.com
IPO Date Nov. 6, 2020
Employees 1008
Officers Andrew Kramer Vice President of Investor Relations Ms. Dana Gerner Chief Financial Officer Mr. Thomas E. Hogan Executive Chairman Ms. Ayala Berler Shapira General Counsel & Chief Compliance Officer Ms. Zohar Tadmor-Eilat Chief People Officer Mr. Leeor Ben-Peretz Chief Strategy Officer Mr. Ronnen Armon Chief Products & Technologies Officer Mr. Marcus Jewell Global Chief Revenue Officer Mr. David Nicholas Gee Chief Marketing Officer